Back to Results

Mesoblast Ltd (MEOBF)

Mesoblast Ltd is an Australia-based biotechnology company focused on regenerative medicine. Its research platform uses mesenchymal lineage cells, a type of specialized cell used in the company’s development programs. The company is working on several clinical-stage candidates, including Remestemcel-L, which is being studied in Phase III trials for inflammatory conditions such as steroid-refractory acute graft versus host disease, biologic-refractory inflammatory bowel disease, ulcerative colitis, Crohn’s disease, chronic heart failure, and chronic low back pain linked to degenerative disc disease. It is also advancing MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy. Mesoblast has collaborations with Tasly Pharmaceutical Group, JCR Pharmaceuticals, and Grünenthal covering selected cell therapy programs. Founded in 2004, the company is headquartered in Melbourne, Australia, and its ordinary shares trade on OTC Markets.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-MEOB.F
$1.38
-18.6% Downside
Overvalued
—
—
—
Good
—
—
—
0.0%
September 2, 2026
-23.4x
3.8x
33.8x
2.114 B
2.216 B
5.8%
64.1%
-9.8
—
64.3%
Send a message
Valuation • Fair Value

Mesoblast Ltd (OTC-MEOB.F) Fair Value by Valuation Model

Compare the primary fair value estimate for Mesoblast Ltd (OTC-MEOB.F) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.38

Estimated downside of 18.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.82

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.24

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Mesoblast Ltd (OTC-MEOB.F) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Mesoblast Ltd (OTC-MEOB.F)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

65.384 M

Current operating scale indicator.

Revenue Forecast

120.3 M

Forward revenue estimate.

EBITDA

-64.339 M

Current operating profitability reference.

EBITDA Forecast

-2.592 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Mesoblast Ltd (OTC-MEOB.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Mesoblast Ltd (OTC-MEOB.F)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

15.47

Higher caution zone on this screen.

Altman Z-Score

-9.8

Lower score that deserves closer risk review.

FCF / Net Income

64.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Mesoblast Ltd (OTC-MEOB.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Mesoblast Ltd (OTC-MEOB.F)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 2, 2026

Days to Earnings

43

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Mesoblast Ltd (OTC-MEOB.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Mesoblast Ltd (OTC-MEOB.F) Stock Forecast & Technical Outlook

Review Mesoblast Ltd (OTC-MEOB.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Mesoblast Ltd (OTC-MEOB.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Mesoblast Ltd (OTC-MEOB.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Mesoblast Ltd (OTC-MEOB.F) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Mesoblast Ltd (OTC-MEOB.F) Stock FAQ

Quick answers about Mesoblast Ltd (OTC-MEOB.F) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.38
Estimated downside 18.6%
Valuation Rating
Overvalued
Estimated downside of 18.6%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Good
Current financial-health read

The current fair value estimate for Mesoblast Ltd (OTC-MEOB.F) is $1.38. This implies an estimated downside of 18.6% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 18.6% versus the current market price.

An analyst price target for Mesoblast Ltd (OTC-MEOB.F) is not currently available in the latest data file.

The current financial health read for Mesoblast Ltd (OTC-MEOB.F) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Mesoblast Ltd (OTC-MEOB.F) is September 2, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Mesoblast Ltd (OTC-MEOB.F) is -23.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Mesoblast Ltd is 2.114 B.

The current enterprise value listed for Mesoblast Ltd is 2.216 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Mesoblast Ltd is OTC-MEOB.F, and the stock is listed on OTC Markets.

Mesoblast Ltd (OTC-MEOB.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Mesoblast Ltd is 5.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Mesoblast Ltd is 64.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)
Medicenna Therapeutics Corp (MDNAF) Medicenna Therapeutics Corp (MDNAF)